Effects of Glycooxidative Stress on Human Aging- Study #3
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Metabolic Syndrome
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Enrollment
- 383
- Locations
- 1
- Primary Endpoint
- Change in Blood Glucose and Insulin levels in 1 year as compared to baseline
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
The investigators have previously demonstrated that Advanced Glycation End products (AGEs) are associated with several chronic diseases in humans and that blood AGE levels can be significantly reduced by simply changing the way food is cooked.
This is an interventional-randomized study in which we are trying to determine whether a diet low in AGE followed for 1 year can effectively reduce circulating AGE levels as well as markers of the metabolic syndrome in a group of patients with these abnormal markers.
Detailed Description
The metabolic syndrome (MetSyn), a well-defined cluster of pathogenic conditions, includes glucose intolerance, insulin resistance (pre-diabetes), hypertension, abdominal obesity, and dyslipidemia. The MetSyn has a strong inflammatory component and raises the risk for cardiovascular disease (CVD) by five-fold and of diabetes by two fold in aging. Although, excessive caloric intake, i.e. "over nutrition" is known to be involved in developing the MetSyn, the actual causative agents of MetSyn in human nutrition have not been determined. The investigators have previously shown that Advanced Glycation End products (AGEs) can induce oxidant stress and inflammatory responses and modulate insulin signaling in animal models and more recently in humans. These studies separated the effects of "over-nutrition" from the pro-inflammatory effects of AGEs, a factor not previously considered. These data support our hypothesis that AGE-restriction could be an important intervention in the MetSyn in aging. The investigators would like to demonstrate that this safe, practical and economical intervention can arrest the progression of three major "epidemics" of aging: diabetes, obesity, and vascular disease associated with the metabolic syndrome. This simple intervention could have significant health and economic implications. Our hypothesis is that dietary AGE restriction can reverse several cardinal manifestation of the MetSyn, specifically insulin resistance, abdominal obesity and cardiovascular disease.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Non-smoking adult subjects with at least three of the following five characteristics of the metabolic syndrome (MetSyn):
- •Waist circumference:
- •Men: \> 102 cm Women: \> 88 cm
- •Blood pressure: \> 130/85 mm Hg (or use of anti-Blood Pressure medication)
- •HDL-cholesterol:
- •Men: \< 40 mg/dL Women: \< 50 mg/dL
- •Triglycerides: \> 150 mg/dL (or use of medications for high triglycerides such as fibrates or nicotinic acid)
- •Fasting blood sugar \> 100 mg/dl (or use of metformin), but a Glycated hemoglobin (HbA1c) \<6.5%
- •Any gender and race 50 years old or above
- •Dietary AGE intake \> 12 AGE Eq/day
Exclusion Criteria
- •Diagnosis of diabetes (HbA1C \> 6.5 %)
- •Glomerular Filtration Rate (GFR) less than 60 ml/min
- •Any major cardiovascular event within the preceding 3 months
- •Inability to understand or unwillingness to follow study diets
- •Any unstable medical condition requiring medication adjustment or treatment within the preceding 3 months
- •Any severe illness with an expected participant survival less than 1 year
- •Diagnosis of HIV
- •Currently receiving treatment for any inflammatory condition
- •Currently receiving cancer treatment, such as radiation, chemotherapy, hormone therapy, or stem cell transplant
- •Currently participating in any other research study requiring a special diet, medications, supplements or other lifestyle change
Outcomes
Primary Outcomes
Change in Blood Glucose and Insulin levels in 1 year as compared to baseline
Time Frame: after 1 year
To test whether prolonged (1 year) dietary AGE restriction, while maintaining caloric intake, can improve insulin resistance in subjects with metabolic syndrome. Insulin resistance will be assessed by measuring simultaneously blood glucose and insulin levels in the fasting state and during an oral glucose tolerance test.
Secondary Outcomes
- Change in markers of cardiovascular disease in 1 year as compared to baseline(after 1 year)
- Change in abdominal obesity in 1 year as compared to baseline(after 1 year)